See you next year in Calgary!

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Thursday, April 11, 2024

}

07:00 – 18:00

North Tower

- Junior Ballroom Foyer

Conference Registration

}

07:00 – 18:00

North Tower

- Junior Ballroom Foyer

Internet Café

}

07:00 – 18:00

North Tower (lower lobby)

- Gulf Island A

Speaker Ready Room

}

07:00 – 18:00

B Tower

- Beluga

Sponsor Lounge – BD

}

07:00 – 18:00

B Tower

- Blue Whale

Sponsor Lounge – Diasorin

}

07:00 – 18:00

South Tower (4th floor)

- Columbia

Sponsor Lounge – bioMérieux

}

07:00 – 18:00

North Tower

- Parksville

Escape Room

07:00 - 17:00
Sign Up (last group entrance 17:00)
}

07:00 – 08:30

North Tower (4th floor)

- Port McNeill

CACMID AGM

}

07:00 – 08:30

North Tower (4th floor)

- Port Alberni

AMMI Canada Communications Committee Meeting

07:00 - 07:30
Breakfast
07:30 - 08:30
Meeting
}

08:30 – 10:00

North Tower

- Grand Ballroom BC

Plenary

Challenges and Advances to Implementing Diagnostics and Care in Rural and Remote Settings in Canada

MODERATORS:
Vanessa Tran (ON)
Ninad Mehta (SK)

SPEAKERS:
David Goldfarb (BC)
Kim Dionne (NU)
John Kim (MB)

At the end of this session, participants should be able to:

  • Review the impact on quality of care and health outcomes for populations with limited access to laboratory medicine
  • Describe specific challenges encountered in the development of laboratory medicine in rural and remote settings
  • Identify strategies and learn about success stories in improving access to laboratory medicine in Canada
}

10:00 – 17:30

North Tower

- Pavilion Ballroom and Junior Ballroom

Exhibit Hall Open / Poster Viewing

}

10:00 – 10:30

North Tower

- Pavilion Ballroom and Junior Ballroom

Break

}

10:30 – 11:30

North Tower

- Grand Ballroom BC

Respiratory Syncytial Virus (RSV) Burden of Disease in Infants – A Need for All Infant Protection

(co-developed learning activity)

MODERATOR:
Prameet Sheth (ON)

SPEAKER:
Cora Constantinescu (AB)

At the end of this session, participants should be able to:

  • Describe the seasonality of RSV and understand the burden of disease related to RSV in all infants
  • Summarize RSV prevention strategies through monoclonal antibodies and maternal vaccines
  • Recognize opportunities for success and potential challenges with the implementation of public RSV prophylaxis programs across Canada

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Sanofi and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

11:30 – 13:00

North Tower

- Pavilion Ballroom and Junior Ballroom

Lunch in Exhibit Hall

}

11:45 – 12:45

North Tower

- Pavilion Ballroom and Junior Ballroom

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Poster Presenters at Posters to Answer Questions

 

TP001 (#4) Culture-independent detection of Helicobacter pylori antimicrobial resistance markers in stool by metagenomic sequencing
Presenting: Kaye Quizon
TP002 (#17) Validation of Copan Amies gel swabs for the detection of Streptococcus pyogenes
in throats on GeneXpert Xpress Group A Strep assay
Presenting: Melissa Caza
TP003 (#44) Determining the limit of detection of antibiotic broth-enrichment, culture based,
and PCR-based methods for the detection of vancomycin-resistant enterococci and carbapenemase-producing Enterobacterales
Presenting: Jay Wieler
TP004 (#52) Evaluation of TB Xpert® MTB/Rif Ultra assay on formalin-fixed paraffin embedded tissues for Mycobacterium tuberculosis diagnosis
Presenting: Shazia Masud
TP005 (#59) Validation of a two commercial serology assays for the detection of antibodies against mpox virus
Presenting: Ana Citlali Marquez
TP006 (#62) Development of an Amplicon-based whole genome sequencing assay for
Respiratory Syncytial Virus
Presenting: Henry Wong
TP007 (#63) Evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel for the detection
of viral and bacterial pathogens in nasopharyngeal swab specimens
Presenting: Melissa Caza
TP008 (#67) Detection of bacteria directly from synovial fluid using digital PCR:
A proof of concept study
Presenting: Corrie Belanger
TP009 (#80) Change in the Streptococcus pyogenes (group A streptococcus, GAS) positivity rates among throat swabs submitted from community settings in British Columbia
Presenting: Eugene Yeung
TP010 (#81) To beat or not to beat–An exploratory assessment of two commercial fecal DNA extraction methods with and without bead-beating for quantitative polymerase chain reaction-based detection of gastrointestinal protozoa
Presenting: LingHui Su
TP011 (#92) Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a diagnostic test accuracy systematic review and meta-analysis
Presenting: Adam Komorowski
TP012 (#105) Low-level (< 1 x 106 cfu/L) Streptococcus agalactiae bacteriuria in pregnancy
is significantly associated with antepartum colonization
Presenting: Ariel Ang
TP013 (#107) Evaluation of the NG-Test® CTX-M MULTI lateral flow immunoassay
Presenting: Geneviève Amaral
TP014 (#108) Investigating the performance of typhoid diagnostics and molecular analysis
of Salmonella entericavirulence
Presenting: Emmanuel Kweku Sam
TP015 (#115) Evaluation of the Seegene STARlet-AIOSTM compared to the conventional STARlet system using the AllplexTM Entero-DR Assay
Presenting: Jay Wieler
TP016 (#117) Monitoring of Legionella pneumophila out breaks through Next Generation Sequencing-based genotyping: Comparison assessment with PFGE and SBT
Presenting: Cindy Lalancette
TP017 (#118) Candida auris identification using CHROMagar™ Candida Plus and qPCR
Presenting: Xiao Rui (Lisa) Li
TP018 (#124) Performance evaluation of complete urine culture categorization by WASPLab PhenoMATRIX
Presenting: Leah Brown
TP019 (#130) Xpert MTB/RIF Ultra performance on bronchoscopy specimens for tuberculosis (TB) diagnosis in a low-incidence setting
Presenting: Cole Schonhofer
TP020 (#144) TaqMan PACMAN: A simple molecular approach for positive rapid antigen test confirmation during periods of low prevalence
Presenting: Jason LeBlanc
TP021 (#144) Incidence rates and serotype distribution of human enteroviruses in patients with central nervous system (CNSI) infections in South-central Ontario
Presenting: Matthew Surette
TP022 (#165) Comparison of fosfomycin (FOS) MICs generated by reference agar dilution (AD) testing and Etest® for pathogens submitted to a Canadian fosfomycin susceptibility testing service
Presenting: Heather Adam
TP023 (#167) Performance of a novel chromogenic agar for primary isolation of pathogenic
beta-hemolytic streptococci from throat swabs
Presenting: Abdulrahman Almodahka
TP024 (#170) Evaluation of the Seegene STARlet-AIOS™ automation system for
respiratory virus testing
Presenting: Lauren Zoppa
TP025 (#177) Evaluation and comparison of five commercial stool antigen assays for the
diagnosis of Helicobacter pylori
Presenting: Lisa Cormier
TP026 (#179) Comparison of genetic resolution in clinical Mycobacterium tuberculosis complex isolates by genotyping and whole genome sequencing methods
Presenting: Angela Ma
TP027 (#180) Bruker™ MALDI-ToF MS Compass Library Revision K accurately discriminates Streptococcus pyogenes from Streptococcus dysgalactiae/canis
Presenting: Nicholas Kontzie
TP028 (#192) Evaluation of the Xpert® MTB/RIF Ultra for the detection of Mycobacterium tuberculosis in cerebrospinal fluids
Presenting: Kerstin Locher
TP029 (#199) Increased seroprevalence of Lyme disease in Nova Scotia: A ten-year update
Presenting: Glenn Patriquin
TP030 (#201) Optimizing Leishmania diagnostics: an integrated molecular approach for accurate detection and species identification
Presenting: Alan O’Dwyer
TP031 (#203) Workflow comparison and evaluation of an automated instrument for handling sample preparation in clinical laboratory
Presenting: Michael Chan
TP032 (#206) Comparing routine C. difficile testing methods to identify C. difficile colonization
in asymptomatic patients prior to hematopoietic cell transplantation
Presenting: Austin Yan
TP033 (#225) Enhancing influenza surveillance through whole genome sequencing: Implications
for local, national, and global pathogen control
Presenting: Kara Loos
TP034 (#227) Comparative performance of the BioFire® FilmArray® respiratory panel 2.1 and the GeneXpert® Xpert® SARS-CoV-2/Flu/RSV assays for the detection of respiratory viruses in children using nasopharyngeal swabs
Presenting: Abdulrahman Almodahka
TP035 (#229) Detection of atypical bacteria, including Mycoplasma pneumoniae, 2013-2023
Presenting: Tess MacIntyre
TP036 (#230) Multicenter experience on the diagnostic yield of multiplex bacterial PCR for sterile site infections
Presenting: Mohammad Hasan
TP037 (#233) Public Health Agency of Canada’s measles and mumps molecular proficiency panel program: a retrospective study examining past results from Canadian laboratories
Presenting: Vanessa Zubach
TP038 (#240) Development and Validation of a Low-Cost Semi-Automated High-Throughput Direct Qualitative Loop Mediated Amplification Assay for the Detection of Streptococcus pyogenes from Throat Swab Specimens
Presenting: Michael Groesche
TP039 (#242) Development of a Real-Time PCR assay for the detection of Aspergillus species
from bronchial specimens
Presenting: Billie Velapatino
TP040 (#253) Carbapenemase-producing Enterobacterales in Alberta from 2013–2023
Presenting: Ashley Williams
TP041 (#256) Status of detection of Pneumocystis jiroveci in Canadian clinical microbiology laboratories by the National Molecular Group (NMG) survey
Presenting: Greg German
TP042 (#262) Evaluation of a commercial lateral flow immunochromatographic assay, the Alere SA PBP2a test, for detection of Penicillin binding protein 2a (PBP2a) in coagulase negative staphylococcus species
Presenting: Esraa Al-Fraihat
TP043 WITHDRAWN
TP044 (#268) Validation of the VITEK®2 AST-N391 susceptibility testing card compared to disc diffusion following 2022 CLSI M100
Presenting: Yerin Lee
TP045 (#269) Trends in antimicrobial resistance among Gram-negative organisms in Toronto, Canada between January 2013 and December 2022 – A notable rise in MDRO and XDRO Klebsiella pneumoniae
Presenting: Yerin Lee
TP046 (#274) Investigating clinical microbiology performance in an external quality assessment (EQA) program: A 5-year cross-sectional analysis
Presenting: Jennifer Wu
TP047 (#282) Hemophilus influenzae screening and isolation in asymptomatic Cystic Fibrosis patients: Is it worth it? A narrative review
Presenting: Arunima Dalai
TP048 (#283) Mycobacterium tuberculosis pseudo-outbreak due to laboratory cross contamination – An epidemiological investigation and phylogenetic analysis
Presenting: Nayla Léveillé
TP049 (#300) Transmission of Mycobacterium tuberculosis, a problem inside Colombian prisons
Presenting: Mariana Herrera Diaz
TP050 (#301) Evaluation of a provincial Hepatitis C Virus nucleic acid testing reflex program
Presenting: Agatha Jassem
TP051 (#307) WITHDRAWN
TP052 (#311) Evaluation of Digital PCR technology for the detection of Mycobacterium tuberculosis DNA in formalin-fixed paraffin-embedded tissues
Presenting: Billie Velapatino
TP053 (#314) Replacing the CLSI disk potentiation assay with a semi-automated, cost effective molecular assay for the identification of ESBL producing Escherichia coli, Klebsiellae spp and Proteus mirabilis from surveillance specimens
Presenting: Candy Rutherford
TP054 (#325) Evaluation of the utility of secondary confirmatory testing for Neisseria gonorrhoeae identification from culture
Presenting: Ellen Avery
TP055 (#327) Road to efficient HIV diagnostic testing: An evaluation of first-time HIV antibody-positive patients receiving follow-up testing in Alberta, Canada, from 2018 to 2023
Presenting: N. Joelle Kasongo
TP056 (#336) An Enhanced National SARS-CoV-2 Surveillance Program: Bringing together genetic and functional characterization of circulating strains to monitor viral antigenicity and the effectiveness of current antiviral therapeutics
Presenting: Charlene Ranadheera
TP057 (#338) A pilot study to use a viability real-time PCR assay as a diagnostic tool for patients experiencing Salmonellosis
Presenting: Surangi Thilakarathna
TP058 (#342) Testing for extragenital Neisseria gonorrhoeae and Chlamydia trachomatis :
at home pharyngeal and rectal self-swabs are non-inferior to those completed
in healthcare settings
Presenting: Vanessa Tran
TP059 (#334) A challenging O166:H15 STEC strain isolation from patients’ stools
Presenting: Surangi Thilakarathna
TP060 (#345) Post-pandemic recrudescence of invasive streptococcal infection: the new epidemiology of pneumococcal bacteremia
Presenting: Geneviève Amaral
TP061 (#354) Diagnosis of Helicobacter pylori Infection in British Columbia – Serology vs. Urea Breath Test
Presenting: Miguel Imperial
TP062 (#357) Discordance in rifampin resistance determination between a commercial molecular test, whole genome sequencing, and phenotypic testing, for a provincially circulating Mycobacterium tuberculosis strain
Presenting: Adrian Kense
TP063 (#364) Impact on turnaround time for Herpes simplex virus (HSV-1/2) testing following implementation of the BioFire FilmArray® Meningitis/Encephalitis Panel in a paediatric hospital
Presenting: Emma Finlayson-Trick
TP064 (#365) Theoretical assessment of BioFire Blood Culture Identification Panel 2 for positive blood culture identification in a tertiary care paediatric/obstetric hospital
Presenting: Inna Sekirov
TP065 (#368) Development of high-throughput extraction methodology for Legionella pneumophila to support outbreak response in Canada
Presenting: Jennifer Tanner
TP066 (#83) Factors associated with paediatric COVID-19 mortality: A Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study
Presenting: Michael Prodanuk
TP067 (#123) Evaluation of self/parent collected oral nasal swabs for respiratory illness in symptomatic children
Presenting: Hannah Nelson
TP068 (#157) Cytomegalovirus transmission in mismatched paediatric solid organ transplant recipients – What factors are at play?
Presenting: Geraldine Huynh
TP069 (#249) Increasing frequency of intracranial complications of sinusitis in children: A single centre retrospective study before and after emergence of SARS-CoV-2
Presenting: Charis Huddle
TP070 (#138) Exploring updates to contact tracing recommendations for potential measles exposure on an airplane
Presenting: Katie Graham
TP071 (#189) A rise in the frequency of carbapenemase-producing Enterobacterales following
an initial decline post COVID-19
Presenting: Ceylon Simon
TP072 (#202) Idexx Legiolert for the detection of Legionella pneumophila: benefits and limitations as a potential alternative to agar culture for public health testing of environmental waters
Presenting: Hyojin Jeong
TP073 (#237) Evaluation of test positivity rate for rotavirus in one province from 2013 to 2023
Presenting: Caroline Quach-Thanh
TP074 (#250) The effect of antimicrobial copper on pathogenic and environmental microorganisms in high-traffic non-clinical settings
Presenting: Kelsey Cruz
TP075 (#284) Could blood establishments help in evaluating whether HTLV-1/2 screening should
be conducted in high-risk pregnant women?
Presenting:Christian Renaud
TP076 (#294) Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in Canadian older adults
Presenting: Sydney George
TP077 (#303) Improving vaccine uptake: Immunization governance in Atlantic Canada
Presenting: Rachel Parker
TP078 (#319) Dried blood spot sampling for HIV, hepatitis C, and syphilis testing: Evaluating provincial implementation of an innovative testing modality
Presenting: Janice Duddy
TP079 (#323) The Community Pop-up Clinic (CPC): Cascade of Care and HCV Treatment in vulnerable population of people who use drugs (PWUD)
Presenting: Shana Yi
TP080 (#346) Impact of new sexual behaviour-based screening practice at Héma Québec
Presenting: Christian Renaud
TP081 (#347) Respiratory Syncytial Virus: the use of the Moving Epidemic Method to guide the launch of palivizumab immunoprophylaxis campaigns in Québec
Presenting: Christian Renaud
TP082 (#355) Molecular Screening Reveals Low Prevalence of Ixodes scapularis ticks in British Columbia: Implications for Tick Identification Methods
Presenting: Isaac Singh
TP083 (#56) Motivation to opt-out of quality improvement project for universal third trimester screening of chlamydia and gonorrhea at a single hospital site in Alberta
Presenting: Taylor Walsh
TP084 (#121) Characterization of Mycoplasma genitalium in Canada from 2022 to 2023
Presenting: Nick Nordal-Budinsky
TP085 (#147) Mycoplasma genitalium infection in a cohort of adolescents and young women
Presenting: Angela Copete
TP086 (#193) Ceftriaxone resistant Neisseria gonorrhoeae strains in Canada, 2017-2023
Presenting: Robyn Thorington
TP087 (#223) Evaluating the Performance of Dried Blood Spot Samples for Sexually Transmitted Blood Borne Infection Testing
Presenting: Jennifer Kopetzky
TP088 (#322) Multiple Syphilis Infections episodes in British Columbia: Molecular Analysis using Enhanced CDC-rpsA Typing and Point Mutation Detection
Presenting: Pink Yi Lui
TP089 (#326) Genomic characterization of circulating Treponema pallidum strains in British Columbia, 2023
Presenting: Min-Kuang Lee
TP090 (#348) Investigation of the newly emerging 14d/d Treponema pallidum strain in British Columbia using multilocus sequence typing
Presenting: Julia Wang
TP091 (#125) Evaluation of the updated cobas® SARS-CoV-2 & Influenza A/B Qualitative nucleic acid test (v2) for the detection of influenza A H1N1 containing matrix mutation C124A
Presenting: Christopher Lowe
TP092 (#159) Targeting Hepatitis B Virus by pretending to be Hepatitis Delta Virus
Presenting: Justine Beghin
TP093 (#211) Detecting proliferation of rubella-specific memory T-cells in the prenatal population
Presenting: Tamara Semeria Maitret
TP094 (#217) Clinical Significance of Human Herpesvirus 6 detected with the Film Array Meningitis/Encephalitis Panel in Nova Scotia
Presenting: Yahya Shabi
TP095 (#286) Characterization of live attenuated and UV-inactivated VSV-based influenza universal vaccine targeting the highly conserved M2 ectodomain from different host strains
Presenting: Titus Olukitibi
TP096 (#334) Identification of nsp5 mutations in SARS-CoV-2 isolates from patients after completion of nirmatrelvir-ritonavir therapy through whole-genome sequencing
Presenting: Natalie Deschenes
TP097 (#248) Epidemiology of paediatric invasive pneumococcal disease (IPD) late after introduction of a routine infant PCV13 program
Presenting: Altynay Shigayeva
}

13:00 – 14:30

North Tower

- Grand Ballroom A

Masterclass C

Oral Antibiotic Therapies for Infections in Paediatrics and Adults - Implications for Infectious Disease and Medical Microbiology

(pre-registration required to maximum of 150 participants)

MODERATOR:
William Connors (BC)

SPEAKERS:
Jennifer Grant (BC)
Amesh Adalja (PA, USA)

At the end of this session, participants should be able to:

  • Understand the evidence for use of oral antibiotics for serious bacterial infections (ie: bacteremia, endovascular infection, deep seated/bone and joint infections)
  • Appreciate the laboratory and clinical challenges of implementing oral antibiotic regimens into routine clinical care
  • Review key areas of uncertainty and barriers to more wide-spread use of oral antibiotics for serious bacterial infection and among patients marginalized in the healthcare system (i.e.: persons who inject drugs, experiencing homelessness)
}

13:00 – 14:30

North Tower

- Grand Ballroom D

Masterclass D

Infectious Issues with Immunotherapy (Monoclonal antibodies, targeted therapies, bispecifics, and cellular therapies)

(pre-registration required to maximum of 150 participants)

MODERATOR:
Peter Pieroni (MB)

SPEAKERS:
David Szwajcer (MB)
Versha Banerji (MB)

At the end of this session, participants should be able to:

  • Describe the prevalence of infectious disease complications of immunotherapy
  • Summarize a standardized approach to working up patients from an infectious disease perspective starting immunotherapy or suffering from an infectious complication
}

14:45 – 15:45

North Tower

- Grand Ballroom BC

State of the Art (START) Lecture

Microbiology and Infections in Transgender and Gender-Diverse Patients

MODERATORS:
Philippe Lagacé-Wiens (MB)
Marthe Charles (BC)

SPEAKERS:
Jessica Prodger (ON)
Emery Potter (ON)
Ben Peto (ON)

At the end of this session, participants should be able to:

  • Review gender affirming care, genital health and factors that may have an impact on the microbiota and infections
  • Describe the appropriate handling and result interpretation of microbiological specimens from gender-diverse patients
  • Understand the patient experience of gender-diverse people in accessing infectious diseases care
}

16:00 – 17:00

North Tower

- Grand Ballroom A

Increasing Cervical Cancer Prevention Worldwide

(co-developed learning activity, pre-registration required to maximum of 150 participants)

MODERATOR:
Prameet Sheth (ON)

SPEAKERS:
Philippe Descamps (FR)
Lananh Nguyen (ON)

At the end of this session, participants should be able to:

  • Summarize why cervical cancer is the fastest growing cancer in Canadian females
  • Describe the WHO recommendations towards elimination of cervical cancer
  • Summarize the international and local responses to the WHO recommendations including the ACCESS International Consensus Group on Cervical Cancer

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Hologic and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

16:00 – 17:00

North Tower

- Grand Ballroom D

Adapting to the Times: Vaccination’s Crucial Role in RSV, Flu, COVID-19, and Pneumococcal Disease

(co-developed learning activity, pre-registration required to maximum of 150 participants)

MODERATOR:
Cora Constantinescu (AB)

SPEAKERS:
Allison McGeer (ON)
Angel Chu (AB)

At the end of this session, participants should be able to:

  • Review the epidemiology of RSV, influenza, COVID-19, and pneumococcal disease
  • Discuss strategies and best practices to help reduce the burden of these common infections
  • Explore how new vaccinations fit into current prevention paradigms

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Pfizer Canada and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

17:00 – 17:15

North Tower

- Grand Ballroom Foyer

Break

}

17:15 – 18:15

North Tower

- Grand Ballroom A

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Oral Presentations Session B

Moderator: William Connors (BC)

17:15 – 17:30
B01 (#61)
Candida auris in Canada, 2012 – Oct 2023
Presenting: Amrita Bharat
17:30 – 17:45
B02 (#358)
Congenital Syphilis in Canada: Clinical and health-care related diagnosis and treatment findings of a Canadian Paediatric Surveillance Program Study
(June 2021-May 2023)
Presenting: Jared Bullard
17:45 – 18:00
B03 (#100)
Mailed antibiotic prescribing feedback to primary care physicians:
A factorial randomized controlled trial
Presenting: Kevin Schwartz
18:00 – 18:15
B04 (#178)
Macrolide and Fluoroquinolone Resistant Mycoplasma genitalium
in Canada, 2018-2023
Presenting: Shelley Peterson
}

17:15 – 18:15

North Tower

- Grand Ballroom D

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Rapid Fire Student Presentations Sessions B

Moderator: Danielle Brabant-Kirwan (ON)

17:15 – 17:20
RFB01 (#69)
Use of Dalbavancin in treatment of Acute Bacterial Skin and Skin Structure Infections: Prospective Case Series from a Canadian Perspective
Presenting: Wayne Leung
17:20 – 17:25
RFB02 (#258)
Verification of the Aptima Bacterial Vaginosis (BV) and
Candida/Trichomonas (CV/TV) assays on the Hologic Panther
Presenting: Emily MacAdam
17:25 – 17:30
RFB03 (#41)
Clinical validation of an optimized and automated agnostic diagnostic
assay for detection of respiratory viruses
Presenting: Nick Gauthier
17:30 – 17:35
RFB04 (#58)
Multivariate analysis of risk factors predicting 28 -day mortality among adult patients presenting with bacteremia in the emergency department
Presenting: Noémie Laurier
17:35 – 17:40
RFB05 (#75)
Infectious diseases consultation is associated with reduced mortality in hospitalized patients with Gram-negative bloodstream infection: a population-wide cohort study
Presenting: Sean Ong
17:40 – 17:45
RFB06 (#198)
HCV Reinfection Among People Who Use Drugs (PWUD) Treated For HCV Infection:
A Long -Term View
Presenting: Saina Beitari
17:45 – 17:50
RFB07 (#213)
Impact of antimicrobial copper surfaces on microbial load and healthcare-acquired infection rates in long -term care settings: a comparative study in Canada
Presenting: Hasan Hamze
17:50 – 17:55
RFB08 (#133)
MRSA isolates resistant to trimethoprim-sulfamethoxazole by VITEK2 and BD
Phoenix antibiotic susceptibility testing systems but susceptible by Etest
and disk diffusion harbour a resistant subpopulation
Presenting: Farhan Khan
17:55 – 18:00
RFB09 (#270)
Validation of Python scripts vs. Excel for cleaning, analysis, and visualization
of surveillance and methods evaluation data
Presenting: Yerin Lee
18:00 – 18:05
RFB10 (#287)
Impacts of SARS -CoV -2 and non-pharmaceutical interventions on the seasonal incidence of hospitalizations for acute respiratory diseases among children
Presenting: Christina Lukac
18:05 – 18:10
RFB11 (#306)
Clinical and public health management of bacterial gastroenteritis in the world of culture -independent diagnostic testing (CIDT): A pilot study to evaluate kinetics
of bacterial shedding by culture and CIDT
Presenting: Nathan McCartney
18:10 – 18:15
RFB12 (#324)
SARS -CoV -2 seropositivity in Alberta: the Omicron era
Presenting: Sa’adiya Umar
}

18:30 – 21:30

South Tower (4th floor)

- Hudson

CFID Board Meeting

}

18:30 – 21:30

North Tower (4th floor)

- Port Alberni

JAMMI Editorial Board Meeting

}

18:30 – 21:30

Various Locations

Unaccredited Learning Activities